COVID-19 vaccines provided high economic returns in first year, study finds
A global economic evaluation shows that the health and financial benefits of COVID-19 vaccines far exceeded the costs of their development, manufacturing, and delivery during the first year.
FTMQ Health, written by our newsroom0 views
The health and economic benefits of COVID-19 vaccines far exceeded the initial investments made to produce and distribute them during the first year of the vaccination programme. PLOS Medicine and Bioengineer.org both report that researchers evaluated the global return on investment by comparing the total expenditures on vaccine development, manufacturing, and delivery against the resulting benefits. Daily Kos reported that the vaccination campaign saved trillions of dollars overall. [1][3][4]
The model-based economic evaluation was conducted by Hallie Benjamin, Gregory Barnsley, Oliver J. Watson, and Mark Jit, according to PLOS Medicine. The study examined national outcomes across multiple countries to assess how vaccine rollouts impacted global health burdens and economic stability. Bioengineer.org reported that the research demonstrated high economic returns across all participating regions. [1][4]
COVID-19 vaccines are designed to generate immunity against SARS-CoV-2, the virus responsible for coronavirus disease 2019. Vaccines help reduce the risk of severe illness, hospitalisation, and death. The World Health Organization declared COVID-19 a public health emergency of international concern in January 2020 and a global pandemic in March 2020. [5][7]
The rapid development and rollout of COVID-19 vaccines required extraordinary global coordination and funding, according to PLOS Medicine. The new findings highlight that substantial financial resources invested in public health interventions can deliver strong long-term economic gains alongside primary medical benefits. [1]
In short
- PLOS Medicine and Bioengineer.org reported that global benefits of COVID-19 vaccines far exceeded the costs of development, manufacturing, and delivery in their first year.
- Daily Kos reported that the global vaccination programme saved trillions of dollars.
- The study was conducted by Hallie Benjamin, Gregory Barnsley, Oliver J. Watson, and Mark Jit as a model-based economic evaluation.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluationPLOS Medicine, 12d ago (the report this story comes from)
- [2]Court certifies class action alleging negligence at LTC home led to COVID-19 deathsGlobal News, 12d ago
- [3]The Covid-19 Vaccine Saved Trillions, a Global Cost-Benefit AnalysisDaily Kos, 11d ago
- [4]COVID-19 Vaccines Yielded High Global Economic Returns in First YearBioengineer.org, 11d ago
Background
- [5]COVID-19 vaccine on Wikipedia
- [6]Pfizer–BioNTech COVID-19 vaccine on Wikipedia
- [7]COVID-19 on Grokipedia
Our newsroom writes these reports with the help of software, from the 7 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Review finds non-drug approaches for low back pain are cost-effectiveTop Stories, 21d ago
- Childhood type 1 diabetes rates returned to normal after pandemic restrictionsMedical Science, 15d ago
- US states offer incentives to attract rural healthcare workersHealth Care, 1d ago
- China long term care insurance pilots boost urban economic productivity initiallyHealth Care, 2d ago
- Health agencies urge Americas to expand long term care systemsHealth Care, 19d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality4h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial2d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.